OSI Pharmaceuticals (OSIP) - formerly Oncogene Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: sammaster who wrote (343)	1/18/2006 7:44:42 AM
From: DewDiligence_on_SI	of 447

do you think being a selective vegf inhibitor will not give [Macugen] a better side effect profile than lucentis? I’m not convinced that Macugen’s safety profile will help it retain sales. Safety isn’t much of a drawing card when efficacy is marginal. do you think that tarceva growth can make up for the shortfall in macugen sales? That depends on what your definition of shortfall is :-) do you think their price has dropped far enough to discount loss of macugen sales already? Possibly it has, but I haven’t followed the cancer and diabetes sides of the business closely since I sold the stock about a year ago. Regards, Dew

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next